Files
Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/165418
Exploring the scope of [Pt2(4-FC6H4)4(μ-SEt2)2] as a precursor for new organometallic platinum(II) and platinum(IV) antitumor agents
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
The new compound [Pt2(4-FC6H4)4(μ-SEt2)2] (A) was prepared and fully characterized. The reactions of compound A with ligands ArCH=NCH2CH2NMe2 (Ar = 2-BrC6H4, 1a; 2,6-Cl2C6H3, 1b; 4-ClC6H4, 1c; 2-Cl,6-FC6H3, 1d) were studied under different conditions and produced platinum(II) compounds [Pt(4-FC6H4)2(ArCH=NCH2CH2NMe2)] (2b−2d), containing a bidentate [N,N′] ligand, as well as cyclometalated platinum(IV) or platinum(II) compounds such as [PtBr(4-FC6H4)2(C6H4CH=NCH2CH2NMe2)] (4a) or [PtCl{(3-FC6H3)(2-XC6H3)CH=NCH2CH2NMe2}] (5b: X = Cl; 5d: X = F), containing a tridentate [C,N,N′] ligand and either a five (4a) or a seven (5b, 5d) membered metallacycle. These compounds exhibit a great antiproliferative activity against non-small lung cancer cells (A549), and the best result was obtained for compound 2c (IC50 = 0.3 ± 0.1 μM). While compounds 5 alter the mobility of plasmid DNA in a similar way to cisplatin, compound 4 was less efficient in removing the supercoils from DNA. In spite of the very low IC50 value obtained for compound 2c, this compound does not interact with DNA, and it is neither an intercalator nor a topoisomerase I inhibitor.
Subject (English)
Citation
Citation
ESCOLÀ JANÉ, Anna, et al. Exploring the scope of [Pt2(4-FC6H4)4(μ-SEt2)2] as a precursor for new organometallic platinum(II) and platinum(IV) antitumor agents. Organometallics. 2014. Vol. 33, num. 7, pags. 1740-1750. ISSN 0276-7333. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/165418